Hitachi General Hospital

Hitachi 317-0077

0 studies enrolling now · 3 studies all time

What they study most

Crohn's Disease, Relapsed or Refractory Multiple Myeloma, Urinary Bladder Neoplasms

Studies at this site

• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
• A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) — Completed